Upadacitinib (ABT-494) for Eczema, Infantile
This study is evaluating whether a drug may help treat severe atopic dermatitis in children.
See full descriptionAbout the trial for Eczema, Infantile
Treatment Groups
This trial involves 7 different treatments. Upadacitinib (ABT-494) is the primary treatment being studied. Participants will be divided into 7 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
About The Treatment
Side Effect Profile for Part 2: Upadacitinib 45 mg / Upadacitinib 45 mg
Eligibility
This trial is for patients born any sex aged 18 and younger. There are 5 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Upadacitinib (ABT-494) will improve 5 primary outcomes in patients with Eczema, Infantile. Measurement will happen over the course of Up to 7 days.
Patient Q & A Section
What are common treatments for eczema, infantile?
Eczema is common, although there is no single treatment that works for all people diagnosed with eczema. Treatments include avoidance of triggers such as food, sunlight, dust, cigarette smoke, and exercise, and symptomatic medication such as topical corticosteroids. There is still the concern that some medications may have undesirable side effects such as tachycardia in young children or irritability in older children or adults. Although less common, there's the option of the surgery of epidermal photorefractive keratectomy. There's no proven treatment that allows people with eczema to go out of their home without wearing at least some form of a medical style face cover.
Can eczema, infantile be cured?
This case study highlights the importance of the early diagnosis and treatment of eczema, particularly in children with atopic or family history of eczema and atopic conditions.
What causes eczema, infantile?
The current understanding of chronic eczema was influenced by the assumption of allergic disorders as the root of the disease at early stages in the history of eczema and its treatment. Nevertheless, it is now known that non-allergic factors play a major role in the development of eczema, and eczema should be divided into non- atopic eczema and atopic eczema. The correct understanding of eczema is the foundation for a correct diagnosis and management.
What is eczema, infantile?
Eczema, infantile, is an inherited disease that often begins in early childhood. The symptoms of eczema, infantile, can be challenging to diagnose and is frequently confused with other dermatologic conditions.
What are the signs of eczema, infantile?
This paper describes the signs and symptoms of eczema in infants of different countries and compares these signs with the signs and symptoms of eczema in adults.
Has upadacitinib (abt-494) proven to be more effective than a placebo?
Recent findings provides compelling evidence that Upadacitinib has superiority over placebo in the maintenance of remissions in adult patients with moderate to profound, steroid-resistant atopic dermatitis in an open, parallel-group, randomized, controlled clinical study.
What are the latest developments in upadacitinib (abt-494) for therapeutic use?
Upadacitinib has shown excellent efficacy in patients with psoriasis. This is an oral, small-molecule drug that targets several of the targets involved in controlling psoriasis and other skin diseases as well. Because this drug is the first inhibitor targeting the TNF pathway with c-Jun N-terminal kinase (JNK) protein kinase as its mechanistic target, it was considered the most promising therapeutic agent for patients with psoriasis. Additional indications of interest have been found in the development of Upadacitinib. These include the treatment of arthritis and Crohn's disease.
Have there been any new discoveries for treating eczema, infantile?
Eczema is a chronic skin condition that has been affecting those who have been experiencing symptoms of eczema since they were infants. Parents may be worried that there are new medical treatments out there and may opt for a surgery for a [dermal filler or wrinkle filler, cosmetic.] Dermal filler and wrinkle filler is an cosmetic surgery that is being used with results that are long lasting.
Does upadacitinib (abt-494) improve quality of life for those with eczema, infantile?
Although safety and efficacy for ECZO were not demonstrated in this small pediatric cohort, it showed good tolerability and was well tolerated and well tolerated by patients. Therefore, patients will likely continue with abt-494 for symptom improvement through continued therapy to reach their primary endpoint(s).
Have there been other clinical trials involving upadacitinib (abt-494)?
Clinical trials have been completed and the drug was approved by the FDA for the treatment of moderate-to-severe rheumatoid arthritis. Although no clinical trials have been performed investigating the use of a single immuno-modulatory compound for the treatment of eczema and atopic dermatitis, these conditions have a high prevalence in the adult population (about 10%), and a recent Cochrane systematic review indicated that other immunomodulatory therapies in development have potential for improving quality of life in people with moderate-to-severe atopic dermatitis. The current development of abt-494 and similar drugs is warranted.
What is the primary cause of eczema, infantile?
In one in three cases in our study, eczema was primary. This is potentially unusual, because for most causes of whelping eczema, the percentage of babies who suffer from eczema drops dramatically in the first three weeks. The reasons responsible for our high rate of primary eczema are not yet determined.